Hybrid model works, but could be better
It's a big corporate environment, and they've settled on a hybrid model that's fine for most. There's definitely room for more flexibility, especially in the pharmaceutical industry.
The hybrid model (3 days in office) is pretty standard for big pharma now, which is a decent compromise. For a Research Scientist, it helps with lab work but also gives some remote time. I appreciate the flexibility on which days you come in.
Sometimes it feels like they could offer more remote work, especially for non-lab focused tasks. The 'in-office' mandate can feel a bit rigid. It's tough when you're working on tight drug development deadlines and need to be fully focused.
Consider reviewing the hybrid policy for specific R&D roles, especially those with less lab dependency. More flexible remote options could boost morale and productivity for many in the Cambridge, MA office.